SUMMARY Digoxin (5 mg/mI) was added to 10-mg and 20-mg pellets of purified primary and secondary amyloid fibrils, a normal human liver and heart homogenate and a homogenate from the heart of a patient with amyloid cardiomyopathy who had not received digitalis. After centrifugation, the supernatants were recovered and assayed for digoxin concentrations. Aliquots from the sediments were studied for the presence of digoxin, using rabbit antidigoxin antiserum and an indirect immunofluorescent technique. The results showed that 0.11-0.13 ng/ml of digoxin bound per milligram of fibrils and could not be separated by repeated washings. elution with citrate or changes in the pH of the buffer. Immunofluorescent studies demonstrated diffusely bright immunofluorescence with the fibril preparation and amyloid heart homogenate when reacted with digoxin and digoxin-specific antiserum. These studies demonstrate that isolated amyloid fibrils bind digoxin and suggest that this interaction may play some role in the sensitivity to digitalis that has been observed in some patients with amyloid cardiomyopathy.
THE PATHOPHYSIOLOGIC ABNORMALITIES that result from amyloid deposition are thought to be caused by replacement of functional tissue by the amyloid fibrils, which have been considered to be inert.' However, the affinity of the amyloid fibril for various dyes, including Congo red2 and Alcian blue,3 and the recent studies that show selective binding to amyloid fibrils of certain proteins, i.e., P-component,4 blood clotting factors5 and the bone-seeking radionuclide technetium methylene diphosphonate,6 suggest that the fibrils may play a more complex role in various organs.
All clinical forms of amyloidosis can involve the heart.' Patients with amyloid cardiomyopathy are allegedly sensitive to digitalis7 8 which may cause abrupt changes in cardiac rhythm or sudden death. In an effort to understand why digitalis preparations could affect the amyloid-laden heart, an in vitro study was carried out to assess the interaction of isolated amyloid fibrils and digoxin, and in particular, to determine whether isolated amyloid fibrils bind digoxin.
Methods

Fibril Preparation
Amyloid fibrils were isolated from the spleens of two patients with primary amyloidosis and one with secondary amyloidosis as described elsewhere.9 The fibrils were washed three times in Tris-buffered saline (TBS) 0.01 M, pH 8.0, containing 10 mM EDTA to free them from any calcium-bound proteins. They were then dialyzed exhaustively against distilled water and lyophilized. All clinical forms of amyloidosis can involve the heart.' Deposits are particularly prominent in primary and in myeloma-associated amyloidosis as well as in heredofamilial types. Focal deposits are extremely common in the aged.20 21 Cardiac arrhythmias, conduction disturbances and indeed sudden death have been attributed to amyloid infiltration of the heart.'9' 22 Although a recent study did not correlate the incidence and severity of electrocardiographic abnormalities with amyloid deposits in the conducting system, 95% of the patients described in that study were in congestive heart failure and presumably on digitalis therapy.23 However, the deleterious efTects of digoxin on the amyloid-laden heart were not mentioned.
We postulate that selective binding of digoxin to amyloid fibrils may enhance the severity of those disturbances of cardiac muscle previously attributed to amyloid per se. However, an opposite effect should be considered: Digoxin, when bound to the amyloid fibrils, may be pharmacologically impotent or unable to activate the myocardial receptors. Indeed, similar binding may occur in the gastrointestinal tract and effect the absorption of orally administered digoxin. Therapeutic judgment regarding the cautious administration of digoxin in patients with cardiac amyloidosis still rests on clinical grounds. Clearly, further studies defining the kinetics of parenteral and oral digoxin administration in experimental amyloid models and in patients with systemic amyloidosis are indicated to define more precisely digoxin-amyloid interaction.
